Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
Olszewski A, Matasar M, Huntington S, Ollila T, Pelcovits A, Tiger Y, Reagan J, Chorzalska A, Morgan J, Pardo M, McMahon J, Donnelly S, Carmody C, Margolis J, Milrod C, Dubielecka P. Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study. Blood 2024, 144: 1644. DOI: 10.1182/blood-2024-193022.Peer-Reviewed Original ResearchMarginal zone lymphomaCytokine release syndromeOverall response rateCR rateComplete responseFollicular lymphomaPartial responseOverall survivalAdverse eventsLugano criteriaImmune augmentationEfficacy analysisFirst-line treatment of FLTEMRA CD8+ T cellsCounts of NK cellsTreatment of follicular lymphomaCD8+ T cellsInterim analysisPhase 2 clinical trialCT-based criteriaCytokine release syndrome eventLow-dose lenalidomideStep-up dosingPatients discontinued treatmentPD-1 expression